| |
Cardiovascular markers (change in regression outcome) |
| Inflammation biomarkers (change in log-transformed regression predictor) |
Isoprostane-to-Creatinine ratio |
Augmentation Index |
Reactive Hyperemia Index |
QTc |
RMSSD |
Triangular Index |
Low frequency variations |
High frequency variations |
Power Ratio |
Systolic blood pressure |
Diastolic blood pressure |
Heart rate |
| C-reactive protein |
0.00, p=0.96 |
-2.22,
p=0.54 |
-0.09, p=0.07 |
1.35, p=0.74 |
-5.76, p=0.37 |
-1.32, p=0.18 |
5.60, p=0.65 |
-22.80, p=0.18 |
0.05, p=0.81 |
1.62, p=0.60 |
-0.09, p=0.97 |
3.43, p=0.23 |
| Tumor necrosis factor-α receptor 1 |
-0.08, p=0.52 |
-6.22,
p=0.54 |
-0.26, p=0.03 |
9.62, p=0.31 |
-10.09, p=0.69 |
-2.13, p=0.41 |
12.78, p=0.70 |
-38.72, p=0.40 |
0.02, p=0.97 |
0.20, p=0.98 |
-3.98, p=0.38 |
14.10, p=0.06 |
| Soluble CD163 |
0.02, p=0.86 |
-14.06, p=0.04 |
-0.11, p=0.17 |
2.71, p=0.68 |
-2.05, p=0.91 |
-1.75, p=0.34 |
28.46, p=0.16 |
1.86
p=0.95 |
0.33, p=0.23 |
5.19, p=0.30 |
2.34, p=0.46 |
9.44, p=0.06 |
| Soluble CD14 |
-0.03, p=0.83 |
-15.37, p=0.25 |
-0.05, p=0.77 |
-4.08, p=0.73 |
11.25, p=0.76 |
0.41, p=0.91 |
9.91, p=0.79 |
-21.07, p=0.72 |
-0.03, p=0.96 |
-2.51, p=0.78 |
2.45, p=0.67 |
13.31, p=0.17 |
| Models estimate the relationship between the change in log-transformed inflammation biomarker and change in cardiovascular marker using ordinary least squares regression, adjusted for baseline values. Bold values represent statistically significant findings.
Abbreviation: QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences.
Reactive hyperemia index is natural log transformed |
|
